BioRestorative Therapies' drug candidate BRTX-100 has successfully passed a safety test and is now moving forward with its Phase 2 clinical trial. The trial focuses on chronic lumbar disc disease, and the independent review board overseeing the trial has unanimously recommended its continuation without any changes to the protocol.
This recommendation from the Data Safety Monitoring Board (DSMB) is the highest distinction they can give, indicating that no changes are needed for the trial to proceed. BioRestorative Therapies has received unanimous approval from the DSMB to continue as planned.
The safety data reviewed by the DSMB provides further confidence in the potential of BRTX-100 as a treatment for chronic lumbar disc disease. This positive outcome opens up new opportunities for BioRestorative Therapies to expand their pipeline and explore additional therapeutic options.